Psych · General adult psychiatry — mood disorders
Treatment-resistant depression
Also known as TRD · Treatment refractory depression · Refractory major depression · Difficult-to-treat depression · Antidepressant non-response · STAR*D sequential depression treatment
Exam-exhaustive fellowship reference on treatment-resistant depression — operational definitions and staging, pseudo-resistance, STAR*D sequential logic, switch and augmentation (lithium, T3, atypical antipsychotics), ECT, rTMS, ketamine/esketamine, psychotherapy, medical exclusion, and measurement-based care. FRANZCP-primary, globally tagged.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
FRANZCPMRCPsychABPNMD-DNBNEET-SS
Red flags
- Active suicidal intent, plan or recent attempt in a patient labelled TRD — escalate care intensity immediately; do not keep iterating incomplete oral trials while risk is uncontrolled
- Psychotic depression, catatonia, or life-threatening poor oral intake — ECT pathway is first-line, not a distant last resort
- Missed bipolarity or mixed features driving 'failed' antidepressant trials — re-screen before further unipolar escalation
- Pseudo-resistance: subtherapeutic dose, premature switch, non-adherence, ongoing substances or untreated medical illness labelled as true TRD
- Lithium toxicity, NMS, serotonin syndrome, or hypertensive crisis on MAOI pathway — medical emergencies
- Ketamine/esketamine: severe hypertension, marked dissociation, or misuse risk without monitoring infrastructure
Meet the patient
A 34-year-old teacher hands you a referral letter that says "failed five antidepressants." You read the list. Two were stopped in week two for nausea. One was sertraline 25 mg for a month. One she never collected from the pharmacy. One worked — until she stopped it herself during a good summer.[2][6]
She is still depressed, still teaching, and quietly rehearsing what she would do if it got worse. She has had zero adequate trials and one very live risk problem.[1][19]
Every registrar reaches for the sixth drug. Every examiner asks the same first question: "Is this actually treatment resistance?" This topic is that question, answered in order.[6][19]
References20ShowHide
- [1]Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report Am J Psychiatry, 2006.PMID 17074942
- [2]Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am J Psychiatry, 2006.PMID 16390886
- [3]Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression N Engl J Med, 2006.PMID 16554525
- [4]Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report Am J Psychiatry, 2006.PMID 16946176
- [5]McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report Am J Psychiatry, 2006.PMID 16946177
- [6]Gaynes BN, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J, et al. Defining treatment-resistant depression Depress Anxiety, 2020.PMID 31638723
- [7]Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry, 2006.PMID 16894061
- [8]Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial Am J Psychiatry, 2013.PMID 23982301
- [9]Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Am J Psychiatry, 2019.PMID 31109201
- [10]Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial JAMA Psychiatry, 2019.PMID 31166571
- [11]UK ECT Review Group Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis Lancet, 2003.PMID 12642045
- [12]O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial Biol Psychiatry, 2007.PMID 17573044
- [13]Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials Psychol Med, 2014.PMID 23507264
- [14]Nelson JC, Papakostas GI Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials Am J Psychiatry, 2009.PMID 19687129
- [15]Crossley NA, Bauer M Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials J Clin Psychiatry, 2007.PMID 17592920
- [16]Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial JAMA, 2017.PMID 28697253
- [17]Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments Can J Psychiatry, 2016.PMID 27486148
- [18]Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments Can J Psychiatry, 2016.PMID 27486154
- [19]Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
- [20]Kroenke K, Spitzer RL, Williams JB The PHQ-9: validity of a brief depression severity measure J Gen Intern Med, 2001.PMID 11556941